BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schilsky ML. Transplantation for inherited metabolic disorders of the liver. Transplant Proc 2013;45:455-62. [PMID: 23498779 DOI: 10.1016/j.transproceed.2013.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Shang S, Cao Q, Han X, Wang Y, Yin C, Zhao L. Assessing Liver Hemodynamics in Children With Cholestatic Cirrhosis by Use of Dual-Energy Spectral CT. AJR Am J Roentgenol 2020;214:665-70. [PMID: 31967500 DOI: 10.2214/AJR.19.22035] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alves-Bezerra M, Furey N, Johnson CG, Bissig KD. Using CRISPR/Cas9 to model human liver disease. JHEP Rep 2019;1:392-402. [PMID: 32039390 DOI: 10.1016/j.jhepr.2019.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ahmad A, Torrazza-Perez E, Schilsky ML. Liver transplantation for Wilson disease. Handb Clin Neurol 2017;142:193-204. [PMID: 28433103 DOI: 10.1016/B978-0-444-63625-6.00016-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
4 Zabaleta N, Hommel M, Salas D, Gonzalez-aseguinolaza G. Genetic-Based Approaches to Inherited Metabolic Liver Diseases. Human Gene Therapy 2019;30:1190-203. [DOI: 10.1089/hum.2019.140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
5 Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015;14:103-113. [PMID: 25496901 DOI: 10.1016/s1474-4422(14)70190-5] [Cited by in Crossref: 381] [Cited by in F6Publishing: 117] [Article Influence: 54.4] [Reference Citation Analysis]
6 Hammad A, Kaido T, Aliyev V, Mandato C, Uemoto S. Nutritional Therapy in Liver Transplantation. Nutrients 2017;9:E1126. [PMID: 29035319 DOI: 10.3390/nu9101126] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
7 Pankowicz FP, Barzi M, Legras X, Hubert L, Mi T, Tomolonis JA, Ravishankar M, Sun Q, Yang D, Borowiak M, Sumazin P, Elsea SH, Bissig-Choisat B, Bissig KD. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun 2016;7:12642. [PMID: 27572891 DOI: 10.1038/ncomms12642] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 12.0] [Reference Citation Analysis]
8 Sirrs S, Hannah-shmouni F, Nantel S, Neuberger J, Yoshida EM. Transplantation as disease modifying therapy in adults with inherited metabolic disorders. J Inherit Metab Dis 2018;41:885-96. [DOI: 10.1007/s10545-018-0141-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]